Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: The NHLBI Exome Sequencing Project

Blood

Volumn 122, Issue 4, 2013, Pages 590-597

  Johnsen, Jill M ^a,b   Auer, Paul L ^c   Morrison, Alanna C ^d   Jiao, Shuo ^c   Wei, Peng ^d   Haessler, Jeffrey ^c   Fox, Keolu ^e   McGee, Sean R ^e   Smith, Joshua D ^e   Carlson, Christopher S ^c   Smith, Nicholas ^e   Boerwinkle, Eric ^d   Kooperberg, Charles ^c   Nickerson, Deborah A ^e   Rich, Stephen S ^f   Green, David ^g   Peters, Ulrike ^c   Cushman, Mary ^h   Reiner, Alex P ^c,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CHROMOSOME; COPY NUMBER VARIATION; FEMALE; GENE FREQUENCY; GENE MAPPING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PSEUDOGENE; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; AGED; BLOOD ANALYSIS; COHORT ANALYSIS; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; NATIONAL HEALTH ORGANIZATION; OPEN READING FRAME; PHYSIOLOGY; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; EXOME; FACTOR VIII; FEMALE; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE; UNITED STATES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84886901150     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-485094     Document Type: Article

References (50)

1. Denis CV, Lenting PJ. von Willebrand factor: at the crossroads of bleeding and thrombosis. Int J Hematol. 2012;95(4):353-361.
2. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol. 2005;42(1):49-55.
3. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9(5):899-908.
4. Johnsen JM, Ginsburg D. von Willebrand disease. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Prchal JT, Seligsohn U, eds. Williams Hematology. 8th ed. New York: McGraw Hill; 2010:2069-2087.
5. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264(33):19514-19527.
6. Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2): 449-458.
7. ISTH-SSC VWF Online Database (VWFdb). http://www.vwf.group.shef.ac.uk/vwd.html. Accessed February 1, 2013.
8. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37(1):89-101.
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
10. Smith NL, Chen MH, Dehghan A, et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382-1392.
11. van Loon JE, Kavousi M, Leebeek FW, Felix JF, Hofman A, Witteman JC, de Maat MP. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost. 2012;10(7):1262-1269.
12. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb. 1994;14(5):686-693.
13. Lutsey PL, Cushman M, Steffen LM, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 2006;4(12):2629-2635.
14. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70(3):380-385.
15. Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost. 2003; 1(10):2191-2197.
16. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
17. Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119(9):2135-2140.
18. Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost. 2013; 11(2):261-269.
19. NHLBI Grand Opportunity Exome Sequencing Project (ESP). https://esp.gs.washington.edu/drupal/. Accessed February 1, 2013.
20. Tennessen JA, Bigham AW, O'Connor TD, et al; Broad GO; Seattle GO; NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012; 337(6090):64-69.
21. Fu W, O'Connor TD, Jun G, et al; NHLBI Exome Sequencing Project. Analysis of 6,515 exomes reveals the recent origin of most human proteincoding variants. Nature. 2013;493(7431): 216-220.
22. Lee H, Schatz MC. Genomic dark matter: the reliability of short read mapping illustrated by the genome mappability score. Bioinformatics. 2012; 28(16):2097-2105.
23. Lettre G, Palmer CD, Young T, et al. Genomewide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet. 2011;7(2): e1001300.
24. Auer PL, Johnsen JM, Johnson AD, et al. Imputation of exome sequence variants into population-based samples and blood-cell-traitassociated loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genet. 2012;91(5):794-808.
25. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet. 2007;81(5):1084-1097.
26. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44(8): 955-959.
27. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8): 904-909.
28. Zheng J, Li Y, Abecasis GR, Scheet P. A comparison of approaches to account for uncertainty in analysis of imputed genotypes. Genet Epidemiol. 2011;35(2):102-110.
29. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002; 70(2):425-434.
30. Lacquemant C, Gaucher C, Delorme C, et al; The GENEDIAB Study Group and the DESIR Study Group. Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. Kidney Int. 2000;57(4):1437-1443.
31. Klemm T, Mehnert AK, Siegemund A, Wiesner TD, Gelbrich G, Blüher M, Paschke R. Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2005;113(10): 568-572.
32. Zabaneh D, Gaunt TR, Kumari M, et al. Genetic variants associated with Von Willebrand factor levels in healthy men and women identified using the HumanCVD BeadChip. Ann Hum Genet. 2011;75(4):456-467.
33. Campos M, Sun W, Yu F, et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood. 2011;117(19): 5224-5230.
34. Kunkel GR, Graham JB, Fowlkes DM, Lord ST. RsaI polymorphism in von Willebrand factor (vWF) at codon 789. Nucleic Acids Res. 1990; 18(16):4961.
35. Strain L, Bonthron DT, Brock DJ. SmaI and HhaI polymorphisms in the 59 region of the human von Willebrand factor gene (F8VWF). Nucleic Acids Res. 1991;19(14):4017.
36. Shahbazi S, Alavi S, Mahdian R. Classification of exon 18 linked variants of VWF gene in von Willebrand disease. Int J Mol. Epidemiol. Genet. 2012;3(1):77-83.
37. Enayat MS, Guilliatt AM, Short PE, et al. A novel alanine or threonine 789 to proline mutation causing type 2N von Willebrand's disease when inherited homozygously or heterozygously with arginine 854 to glutamine mutation. Haemophilia. 2010;16(6):966-969.
38. Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood. 1996;87(3):1013-1021.
39. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood. 2007;109(1):145-154.
40. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
41. Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009;7(8):1304-1312.
42. Flood VH, Gill JC, Morateck PA, et al. Gain-offunction GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011;117(6): e67-e74.
43. Julenius K, Mølgaard A, Gupta R, Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology. 2005;15(2): 153-164.
44. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor - too sweet for their own good. Haemophilia. 2010; 16(Suppl 5):194-199.
45. Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA. O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood. 2012;120(1): 214-222.
46. Berber E, Pehlevan F, Akin M et al. A common VWF exon 28 haplotype in the Turkish population [published online ahead of print March 4, 2013]. Clin Appl Thromb Hemost.
47. Badirou I, Kurdi M, Legendre P, et al. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS ONE. 2012;7(5):e37508.
48. Desch KC, Ozel AB, Siemieniak D, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA. 2013; 110(2):588-593.
49. González-Pérez A, López-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011;88(4):440-449.
50. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology (Am Soc Hematol Educ Program). 2009;106-112.